3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Pheochromocytoma
5
Paraganglioma
4
Neuroblastoma
4
Neuroendocrine Tumors
2
Neuroectodermal Tumors
1
Neoplasms
1
Disease
1
Interventions
Oncolytic Virotherapy
2
vorasidenib
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
Vorinostat
1
Radiation
1
ONC206
1
Interferon-gamma
1
Immunotherapy
1
Antibodies, Monoclonal
1
Afatinib
1
3-Iodobenzylguanidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neuroectodermal Tumors
×
3-Iodobenzylguanidine
×
Clear all
NCT03561259
2023-02-16
OPTIMUM
Jubilant DraxImage Inc.
Phase 2
Unknown
60 enrolled